Why Neurocrine Biosciences, Inc. (NBIX) Stock Fell 10.1% on Jul 31, 2026

Why did NBIX stock fall?

Neurocrine Biosciences fell 10.1% on July 31, 2026, closing at $166.80 — the first full session after it reported second-quarter results on the evening of July 30, and one day after the stock set a 12-month high of $186.12. The quarter itself was strong: total revenue grew 39% year over year to $959.0 million, ahead of published consensus, with non-GAAP diluted EPS of $2.85 against $1.65 a year earlier, and the company raised its full-year INGREZZA net sales guidance to $2.825–$2.875 billion from $2.70–$2.80 billion. Operating expense guidance was raised as well, and the market appears to have read the combined update as offering limited additional upside from a record-high starting price.

• •
  A clear top- and bottom-line beat: Total revenue of $959.0 million rose 39% year over year and came in above published consensus estimates, which ranged roughly $877–$902 million across providers. GAAP diluted EPS was $1.39 and non-GAAP diluted EPS $2.85, versus $1.06 and $1.65 respectively a year earlier.
• •
  INGREZZA guidance raised, but it is the only product range given: Full-year INGREZZA net sales guidance went to $2.825–$2.875 billion from $2.70–$2.80 billion. INGREZZA is the only product-sales range Neurocrine guides — the company does not provide total-company revenue guidance — so the raise covered one franchise rather than the whole business.
• •
  The expense outlook was also revised upward: Full-year non-GAAP SG&A guidance rose to $1,325–$1,350 million from $1,240–$1,265 million and non-GAAP R&D to $1,140–$1,190 million from $1,110–$1,160 million; on a GAAP basis SG&A rose by about $200 million at the midpoint, and a new $85–$90 million amortization line was added. This increase is company-wide — it includes Soleno and VYKAT XR operating costs, integration and purchase-accounting effects, and broader pipeline spend — so it is not a like-for-like offset against the INGREZZA raise.
• •
  The stock went in at a record high: Shares closed July 30 at $185.50 after touching a 12-month high of $186.12, having climbed from roughly $155 in late May. Volume on the decline reached 4.6 million shares against a roughly 1.2 million average.
• •
  The sell side stayed positive: Price targets were raised almost across the board on July 31 — RBC to $198, TD Cowen to $220, BofA to $214, Deutsche Bank to $190, Cantor Fitzgerald to $215, Morgan Stanley to $196, Needham to $204 and Citigroup to $249 — with Wells Fargo explicitly recommending buying the weakness. The consensus target sat near $199.50.

How the story developed

• January 2026Neurocrine sold Neurocrine Group Limited, recognising a $28.6 million pre-tax gain, net of transaction costs.
• May 18, 2026The $2.9 billion acquisition of Soleno Therapeutics closed at $53.00 per share in cash, adding VYKAT XR for hyperphagia in Prader-Willi syndrome and roughly $2.2 billion of intellectual property to the balance sheet.
• May 2026The company entered a $1.0 billion senior secured revolving credit facility; it remained fully undrawn at June 30.
• July 30, 2026Second-quarter results were released after the close, with a conference call at 4:30pm ET. Shares closed at $185.50, having set a 12-month high of $186.12.
• July 31, 2026The stock fell 10.1% to $166.80 on 4.6 million shares, while price targets were raised across most of the sell side.
• August 3, 2026Target increases continued — Wedbush to $194 from $185 and Canaccord to $210 from $200 — as the shares steadied near $166.

What it could mean for NBIX investors

Initial detection

BestStocks first flagged NBIX intraday on Jul 31, 2026; this analysis was finalized after the close using the confirmed −10.1% session move and additional catalyst research.

Other developments that session

Frequently asked questions